INT131286

From wiki-pain
Revision as of 16:37, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2002
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 26
Total Number 27
Disease Relevance 13.58
Pain Relevance 0.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Egfr) cell morphogenesis (Egfr) Golgi apparatus (Egfr)
endoplasmic reticulum (Egfr) intracellular (Egfr) enzyme binding (Egfr)
Anatomy Link Frequency
hepatocyte 1
unspecified 1
arm 1
Atlas 1
Egfr (Mus musculus)
Pain Link Frequency Relevance Heat
Opioid 46 93.40 High High
metalloproteinase 17 84.36 Quite High
opioid receptor 24 81.80 Quite High
positron emission tomography 48 79.36 Quite High
imagery 62 78.20 Quite High
agonist 21 76.08 Quite High
Potency 8 75.20 Quite High
Kinase C 29 71.44 Quite High
Neuronal excitability 1 69.60 Quite High
substance P 4 68.08 Quite High
Disease Link Frequency Relevance Heat
Renal Cell Carcinoma 100 99.84 Very High Very High Very High
Cancer 810 99.68 Very High Very High Very High
Glioma 44 99.68 Very High Very High Very High
Renal Cancer 38 98.96 Very High Very High Very High
Apoptosis 100 98.76 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 3 98.56 Very High Very High Very High
Necrosis 25 98.32 Very High Very High Very High
Ovarian Cancer 39 98.28 Very High Very High Very High
Reprotox - General 1 80 98.12 Very High Very High Very High
Pancreatic Cancer 467 98.06 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, we have previously shown that the positive staining with the 528 antibody, which recognizes an unspecified extracellular epitope of the EGFR, is highly correlated with EGFR amplification [9].
EGFR Binding (recognizes) of in unspecified
1) Confidence 0.44 Published 2005 Journal J Transl Med Section Body Doc Link PMC1298339 Disease Relevance 0.58 Pain Relevance 0.03
Upon ligand binding, the EGFR undergoes homodimerization or heterodimerization.
EGFR Binding (binding) of
2) Confidence 0.37 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.29 Pain Relevance 0.03
In contrast, TKIs, by competitively binding to the ATP binding site of the intracellular domain of EGFR, inhibit EGFR autophosphorylation and impair downstream signaling, leading to cell cycle arrest and apoptosis in vitro (Moyer et al 1997; Pollack et al 1999; Arteaga 2001; Grunwald and Hidalgo 2003; Pao and Miller JCO 2005; Marshall 2006).
EGFR Binding (binding) of associated with apoptosis
3) Confidence 0.37 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.35 Pain Relevance 0
DsRNA specific for EGFR also inhibited tumor cell growth
EGFR Binding (specific) of associated with cancer
4) Confidence 0.37 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.10 Pain Relevance 0
DsRNA specific for EGFR inhibited tumor growth in vivo
EGFR Binding (specific) of associated with cancer
5) Confidence 0.37 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.60 Pain Relevance 0
Thus, tracer binding to EGFR could be influenced by the activation of the tyrosine kinase domain of the receptor which was similar in U138MG and U87MG.
EGFR Binding (binding) of
6) Confidence 0.37 Published 2010 Journal Mol Imaging Biol Section Body Doc Link PMC2978890 Disease Relevance 0.48 Pain Relevance 0.14
EGFR status was not significantly associated with response to erlotinib.
EGFR Binding (associated) of
7) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.95 Pain Relevance 0
More recently, lapatinib (Tykerb®, GlaxoSmithKline, Philadelphia, PA, USA), an oral TKI directed against both EGFR and the associated HER family member HER-2, has been approved for use in women with advanced HER-2 (+) breast cancer.
EGFR Binding (associated) of associated with breast cancer
8) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.68 Pain Relevance 0
Two principal mechanisms of therapeutic EGFR inhibition have been developed: monoclonal antibodies (mAbs) that bind to the extracellular domain of EGFR, and TKIs that inhibit the intracellular tyrosine kinase domain.
EGFR Binding (bind) of
9) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.53 Pain Relevance 0
In our study, however, the respective median overall survival times for our patients under 55 years of age whose tumors expressed neither type of EGFR, overexpressed wild type EGFR or expressed EGFRvIII, were not statistically different.
EGFR Neg (neither) Binding (type) of associated with cancer
10) Confidence 0.34 Published 2005 Journal J Transl Med Section Body Doc Link PMC1298339 Disease Relevance 0.23 Pain Relevance 0
Another important consideration with regards to the mode of action of EGFR inhibitors such as erlotinib is that whilst these drugs have been designed to target the EGFR, it appears that quantification of the target per se in preclinical models may not predict for responsiveness to inhibition.
EGFR Binding (target) of
11) Confidence 0.34 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936363 Disease Relevance 0.38 Pain Relevance 0.04
In pancreatic cancer, preclinical studies suggest EGFR mutations are infrequent, making it difficult to assess their association with responsiveness to anti-EGFR therapy (Kwak et al 2006; Lee et al 2007; Tzeng et al 2007a).
anti-EGFR Binding (association) of associated with pancreatic cancer
12) Confidence 0.33 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.39 Pain Relevance 0
The cold area indicated by the solid arrow in the U138MG EGFR?
U138MG EGFR Binding (indicated) of
13) Confidence 0.32 Published 2010 Journal Mol Imaging Biol Section Body Doc Link PMC2978890 Disease Relevance 0.63 Pain Relevance 0.07
Structural and functional characterization of the iNOS promoter has identified binding elements for both EGFR and STAT3 (Lo et al. 2005).
EGFR Binding (binding) of
14) Confidence 0.31 Published 2007 Journal Transgenic Res Section Body Doc Link PMC1829418 Disease Relevance 0.67 Pain Relevance 0
Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice.
EGFR Binding (ligands) of in hepatocyte associated with apoptosis and hepatitis
15) Confidence 0.29 Published 2010 Journal J. Clin. Invest. Section Title Doc Link 20628198 Disease Relevance 0.99 Pain Relevance 0.11
DSLET activates ERK even in a cell line devoid of the EGFR
EGFR Binding (line) of
16) Confidence 0.29 Published 2002 Journal BMC Pharmacol Section Body Doc Link PMC88976 Disease Relevance 0.18 Pain Relevance 0.16
In this report, we questioned whether the EGFR acts as a surrogate scaffold during ERK activation through the ?
EGFR Binding (surrogate) of
17) Confidence 0.29 Published 2002 Journal BMC Pharmacol Section Body Doc Link PMC88976 Disease Relevance 0 Pain Relevance 0.07
For example, cetuximab and trastuzumab bind to the EGFR and HER-2/neu receptor TKs respectively; these molecules are often overexpressed in colorectal (EGFR) and breast (HER-2/neu) cancers and the efficacy of cetuximab in the treatment of metastatic colorectal cancer (Cunningham et al 2004) and trastuzumab in the treatment of breast cancer (Slamon et al 2001; Piccart-Gebhart et al 2005; Romond et al 2005) has been demonstrated clearly.
EGFR Binding (bind) of associated with cancer, breast cancer and colon cancer
18) Confidence 0.26 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.78 Pain Relevance 0
Multiple studies have demonstrated interaction with EGFR by one of the aforementioned means can affect prostate cancer cell growth and invasion in PC3 and DU145 cells [17].
EGFR Binding (interaction) of associated with reprotox - general 1
19) Confidence 0.24 Published 2004 Journal Cell Commun Signal Section Body Doc Link PMC449737 Disease Relevance 0.50 Pain Relevance 0.03
, a known ligand for EGFR, is commonly elevated in RCC and cell line models demonstrating a correlation between EGFR inhibition and suppression of VEGF expression.25,26 In their single-arm, phase 2 trial, all patients were nephrectomized, and 68% were treatment-naïve.
EGFR Binding (ligand) of in arm associated with renal cancer
20) Confidence 0.21 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2962304 Disease Relevance 0.33 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox